Beta-blockers vs calcium channel blockers for afib

Multicenter Study

. 2017 Nov;24(11):1334-1348.

doi: 10.1111/acem.13303.

Affiliations

  • PMID: 28853232
  • DOI: 10.1111/acem.13303

Free article

Multicenter Study

Rate Control With Beta-blockers Versus Calcium Channel Blockers in the Emergency Setting: Predictors of Medication Class Choice and Associated Hospitalization

Clare L Atzema et al. Acad Emerg Med. 2017 Nov.

Free article

Abstract

Objectives: Rate control is an important component of the management of patients with atrial fibrillation (AF). Previous studies of emergency department (ED) rate control have been limited by relatively small sample sizes. We examined the use of beta-blockers (BBs) versus nondihydropyridine calcium channel blockers (CCBs) in ED patients from 24 sites and the associated hospital admission rates.

Methods: In this preplanned substudy, we examined chart data on AF patients who visited one of 24 hospital EDs in Ontario, Canada, between April 2008 and March 2009. We describe the proportion of patients who received either a BB or a CCB, had a heart rate < 110 beats/min 2 hours later, and had any complications. We used hierarchical logistic regression modeling to determine the predictors of BB versus CCB use and to assess the between-hospital variation in use of BBs versus CCBs. Solely in patients who had no rhythm control attempts, we examined the difference in the probability of hospital admission after propensity score matching patients by medication class.

Results: Of the 1,639 patients who received either a BB (n = 429) or a CCB (n = 1,210), 70.9% of the patients who received a BB had successful rate control versus 66.1% for a CCB. Complications were rare (2.4%), and the large majority were hypotension (2.0%). In adjusted analyses, predictors of receiving a BB (compared to a CCB) included already being on a BB, being sent in from a doctor's office, or being seen at a teaching hospital. In contrast, patients with evidence of heart failure, prior use of a CCB, a higher presenting heart rate, or a successful pharmacologic cardioversion (vs. no attempt) or who were seen at the highest AF volume EDs were significantly less likely to receive a BB, compared to a CCB. Systematic between-hospital differences accounted for 8% of the variation in BB versus CCB use. Hospital characteristics accounted for the large majority of that variation: after accounting for patient characteristics the between-hospital variation decreased by a relative 2.8%. By further adjusting for hospital characteristics, it decreased by a relative 74.7%. Among propensity score-matched patients with no rhythm control attempts, more CCB patients were admitted (51.6%) compared to BB patients (40.0%; difference of 11.6%; 95% confidence interval = 7.9%-16.2%).

Conclusions: In this study of 24 EDs, CCBs were used more frequently for rate control than BBs, and complications were rare and easily managed using both agents. Variation between hospitals in BB versus CCB use was predominantly due to hospital characteristics such as teaching status and AF volumes, rather than different case mix. Among patients who did not receive attempts at rhythm control, use of a BB for rate control was associated with a lower rate of hospitalization.

© 2017 by the Society for Academic Emergency Medicine.

Similar articles

  • Safety and efficiency of calcium channel blockers versus beta-blockers for rate control in patients with atrial fibrillation and no acute underlying medical illness.

    Scheuermeyer FX, Grafstein E, Stenstrom R, Christenson J, Heslop C, Heilbron B, McGrath L, Innes G. Scheuermeyer FX, et al. Acad Emerg Med. 2013 Mar;20(3):222-30. doi: 10.1111/acem.12091. Acad Emerg Med. 2013. PMID: 23517253

  • Comparative persistence on β-blockers versus calcium channel blockers for ventricular rate control in nonelderly patients with atrial fibrillation.

    Desai VC, Kelton CM, Metzger AH, Cavanaugh TM, Guo JJ, Heaton PC. Desai VC, et al. Ann Pharmacother. 2014 Dec;48(12):1570-9. doi: 10.1177/1060028014552819. Epub 2014 Oct 3. Ann Pharmacother. 2014. PMID: 25280975

  • Heart rate outcomes with concomitant parenteral calcium channel blockers and beta blockers in rapid atrial fibrillation or flutter.

    Alowais SA, Hayes BD, Wilcox SR, Le J, Koehl JL, Fuh L. Alowais SA, et al. Am J Emerg Med. 2021 Jun;44:407-410. doi: 10.1016/j.ajem.2020.04.093. Epub 2020 May 8. Am J Emerg Med. 2021. PMID: 32448773

  • Canadian Cardiovascular Society atrial fibrillation guidelines 2010: rate and rhythm management.

    Gillis AM, Verma A, Talajic M, Nattel S, Dorian P; CCS Atrial Fibrillation Guidelines Committee. Gillis AM, et al. Can J Cardiol. 2011 Jan-Feb;27(1):47-59. doi: 10.1016/j.cjca.2010.11.001. Can J Cardiol. 2011. PMID: 21329862

  • Pharmacology, pathophysiology and management of calcium channel blocker and beta-blocker toxicity.

    DeWitt CR, Waksman JC. DeWitt CR, et al. Toxicol Rev. 2004;23(4):223-38. doi: 10.2165/00139709-200423040-00003. Toxicol Rev. 2004. PMID: 15898828 Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

  • Full Text Sources

    • Ovid Technologies, Inc.
    • Wiley
  • Other Literature Sources

    • scite Smart Citations
  • Medical

    • MedlinePlus Health Information
  • Miscellaneous

    • NCI CPTAC Assay Portal

Why use a calcium channel blocker instead of a beta blocker?

Beta blockers are widely recommended for patients with coronary heart disease; however, they can potentially induce DES-VSA. For prevention of naturally occurring vasospastic angina, calcium channel blockers are recommended which may also offer protection against DES-VSA though evidence is scarce.

What is the first drug of choice for atrial fibrillation?

Beta blockers and calcium channel blockers are the drugs of choice because they provide rapid rate control. These drugs are effective in reducing the heart rate at rest and during exercise in patients with atrial fibrillation.

When should you take beta

Pulmonary disease Calcium channel blockers should be favored over beta blockers in patients with asthma (or other forms of pulmonary disease with a bronchospastic component) given the risk of exacerbating bronchospasm.

What is the best medication to control AFib?

A beta blocker, such as bisoprolol or atenolol, or a calcium channel blocker, such as verapamil or diltiazem, will be prescribed. The medicine you'll be offered will depend on what symptoms you're having and your general health.

Toplist

Última postagem

Tag